HOW ITNS WILL HIT .05 by Mid JULY -
The following information is not intended to be meant as a hyping mechanism, nor does it include information not already known. It is simply a basic "X + Y = Z" equation of common sense based on what we do already know.
Invalid fears and concerns eliminated -
Up until recently one of the main things keeping ITNS down was lingering fears that Itonis main product Emesyl was not really in development. We now know that it is.
Key production steps achieved -
All of the below information is verifiable per company and government filings:
- There has been a finalization of the actual ingredients of the homeopathic remedy.
- The FDA has registered Emesyl.
- Itonis has verifiable contracts with Oasis regarding production.
- Oasis (which is only a customer of Itonis, not an affiliate) has verified production is taking place.
- Product packaging design has been completed with bar codes and other necessary technical required data.
Why Emesyl will garner much attention as a promising product -
- Emesyl's function is to relieve nausea. Nausea is an issue for almost all people on the planet either regularly or occasionally.
- Emesyl is homeopathic, a modern (yet ancient) type of "medicine" that is fast gaining more respect and validity in the mainstream culture, and even gaining ground in Western Medicine.
- The inventor of Emesyl is the same Doctor who developed Zicam, a household name recognized worldwide.
- The vast array of causes for necessity of such a product are almost innumerable, from chemo to pregnancy to everyday nausea, it would make sense that most people would keep a bottle of this type of product in their medicine cabinet the same way almost all of us have Tylenol or Ibuprofen.
The promise -
A product like Emesyl is such a strong and revolutionary idea, it will hold great promise both to those who need such a product as well as those who see it purely as an investment opportunity.
